Table 4.
Proliferation, plasmablast differentiation and release of immunoglobulin after 6-day stimulation with CpG/IL-2 of CSR patients and CSR-like CVID patients
| CpG/IL-2 | ||||||
|---|---|---|---|---|---|---|
| Identifier | Proliferation | CD27++ | CD38++ | CD20dull | IgG | IgM |
| Adult control | + | + | + | + | + | + |
| Cord blood | + | +/− | +/− | +/− | − | ++ |
| CD40L | + | +/− | +/− | − | − | +/− |
| AID | + | + | + | + | − | ++ |
| UNG | + | +/− | + | − | − | + |
| Patient #1 | + | + | + | + | − | ++ |
| Patient #2 | + | +/− | + | − | − | + |
| Patient #3 | + | + | + | + | − | +/− |
| Patient #4 | + | +/− | +/− | − | − | +/− |
| Patient #5 | +/− | − | − | − | − | +/− |
Proliferation (measured by CFSE dilution), differentiation into plasmablast (phenotypical markers (CD27++, CD38++, and CD20dull)) and release of immunoglobulin into the supernatant (by ELISA) after stimulation with CpG/IL-2 are scored in comparison with healthy adult controls: ++ (above controls), + (average), +/− (below controls) or – (absent). All data shown are gated on the CD19+ B cell population. Adult control (N = 25), cord blood (N = 15), CSR patients and CSR-like CVID patients (N = 3–5)